CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Government health care insurance, reimbursement policies and the increase in health
care expenditure
4.1.2. Growth in health care awareness among people and an increase in the prevalence of
autoimmune diseases
4.1.3. High incidence of autoimmune diseases
4.1.4. Laboratory automation and emerging markets in Asia
4.2. Market Restraints & Challenges
4.2.1. Lack of skilled professionals, diagnostic errors coupled with stringent regulations for
product approval
4.2.2. The requirement of significant capital to purchase high-cost equipment and
implementation of excise duty on medical devices
CHAPTER 5 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET – BY
TECHNIQUE
5.1. Immunofluorescence Assay
5.2. Multiplex Assay
5.3. Elisa
CHAPTER 6 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET – BY
PRODUCT
6.1. Systems
6.2. Software & Services
6.3. Reagents & Assay Kits
CHAPTER 7 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET – BY
DISEASES
7.1. Sjögren’s Syndrome
7.2. Scleroderma
7.3. Rheumatoid Arthritis
7.4. Systemic Lupus Erythematosus
7.5. Others
CHAPTER 8 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET – BY END USER
8.1. Clinical Laboratories
8.2. Physician Office Laboratories
8.3. Hospitals
8.4. Others
CHAPTER 9 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET - BY
GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET - COMPANY
PROFILES
10.1. ERBA Diagnostics, Inc.
10.2. Antibodies Inc.
10.3. PerkinElmer Germany Diagnostics GmbH
10.4. Immuno Concepts N.A. Ltd.
10.5. Inova Diagnostics, Inc.
10.6. Zeus Scientific, Inc.
10.7. Thermo Fisher Scientific, Inc.
10.8. Abbott Laboratories, Inc.
10.9. Bio-Rad Laboratories, Inc.
10.10. Trinity Biotech PLC
CHAPTER 11 GLOBAL ANTINUCLEAR ANTIBODY TEST MARKET –
COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12 MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13 APPENDIX
13.1. List of Tables
13.2. List of Figures
